Ilyang to spur vaccine development

Published: 2011-01-27 06:57:00

Updated: 2011-01-27 06:57:00

In an effort to develop a variety of vaccines for influenza, food and mouth disease, dengue fever and rabies, Ilyang Pharmaceutical Co, signed a memorandum of understanding with Taiwan based Medigen Biotechnology Corporation on January 18 to make joint research and development based on the latter...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK